Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPATE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Social anxiety disorder,Obsessive-compulsive disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
50 mg orally once daily.
250 mg orally twice daily
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hepatic primarily via CYP2C19, CYP2D6, CYP3A4, and CYP2C9; active metabolite desmethylsertraline.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
95-98% bound, primarily to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.5-0.7 L/kg (suggests moderate tissue penetration; primarily extracellular distribution).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 70-80% (first-pass metabolism 20-30%; food reduces absorption by 10-15%).
70-90% (oral); 100% (IV).
No dosage adjustment required for GFR ≥30 m L/min; GFR <30 m L/min: not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric use.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No dosage adjustment required; monitor renal function.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Suicidality risk in pediatric/young adult patients,Serotonin syndrome risk with concomitant serotonergic drugs,Bleeding risk with anticoagulants/antiplatelets,Activation of mania/hypomania,Seizure risk in patients with epilepsy,Angle-closure glaucoma risk,Hyponatremia risk in elderly/dehydrated patients,Discontinuation syndrome with abrupt cessation
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Concurrent MAOIs (including linezolid and methylene blue),Concurrent pimozide,Known hypersensitivity to sertraline
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Grapefruit and grapefruit juice may increase sertraline levels; avoid consumption.,Alcohol: Avoid or limit intake to prevent worsening of side effects and reduced drug efficacy.,St. John's Wort: Concomitant use increases risk of serotonin syndrome; avoid.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. For all trimesters, increased risk of spontaneous abortion and stillbirth has been reported.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
SERPATE is excreted into human breast milk. Milk-to-plasma ratio is approximately 2:1. Breastfeeding is not recommended during therapy due to potential for severe adverse reactions in the nursing infant. Advise women to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Due to significant pharmacokinetic changes in pregnancy, including increased clearance (by 50%) and expanded volume of distribution, the dose of SERPATE should be increased by 30% during the second and third trimesters. Monitor therapeutic drug levels to maintain trough concentrations within the target range. Postpartum, reduce to prepregnancy dose within 48 hours to avoid toxicity.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
SERPATE is a brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI). Initiate at 25-50 mg daily, titrate up to 200 mg maximum. Monitor for serotonin syndrome, especially with other serotonergic drugs. Abrupt discontinuation may cause withdrawal symptoms; taper gradually. Use with caution in bipolar disorder due to risk of manic switching. Adjusted dosing may be needed in hepatic impairment; no adjustment for renal impairment. May increase risk of bleeding, especially with NSAIDs or anticoagulants. Monitor for hyponatremia in elderly or volume-depleted patients.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take sertraline exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to feel full benefit; do not stop abruptly without consulting your doctor.,Common side effects include nausea, diarrhea, dry mouth, dizziness, and trouble sleeping; these often improve over time.,Contact your doctor immediately if you experience signs of serotonin syndrome (e.g., agitation, hallucinations, fever, fast heart rate, muscle stiffness, twitching, coordination problems) or bleeding (e.g., unusual bruising, nosebleeds).,Avoid alcohol, as it can worsen side effects and reduce drug effectiveness.,Inform all healthcare providers that you are taking sertraline, especially before surgery or any procedure.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPATE vs ALDOCLOR-250, answered by our medical review team.
SERPATE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPATE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPATE is: 50 mg orally once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPATE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPATE is classified as Category C. SERPATE is contraindicated in pregnancy. First trimester exposure carries risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.